急性缺血性卒中静脉溶栓后神经功能恢复与出血转化的影响因素分析
该回顾性单中心研究纳入173例接受rt-PA静脉溶栓的急性缺血性卒中患者,分为出血转化组46例与非出血转化组127例。多因素Logistic回归显示SUA>364.5 μmol/L为HT保护因素(OR=0.607,95%CI 0.493-0.732),年龄>69岁(OR=2.470,95%CI 1.438-5.291)、溶栓前NIHSS>12分(OR=5.072,95%CI 1.793-12.468)、发病至溶栓3.0-4.5小时(OR=3.854,95%CI 1.600-5.816)为HT独立危险因素。eGFR>102.5 mL×min-1×1.73 m-2与SUA>352.7 μmol/L为预后良好保护因素,年龄>70岁、溶栓前NIHSS及HT为预后不良危险因素。
要点
- 溶栓前NIHSS>12分是HT独立危险因素(OR=5.072,95%CI 1.793-12.468,P=0.001),床旁应重点评估。
- 发病至溶栓时间3.0-4.5小时者HT风险显著升高(OR=3.854,95%CI 1.600-5.816,P=0.005)。
- 年龄>69岁为HT独立危险因素(OR=2.470,95%CI 1.438-5.291,P=0.020)。
- SUA>364.5 μmol/L对HT有保护作用(OR=0.607,95%CI 0.493-0.732,P=0.012),但不可据此补尿酸。
- HT是预后不良的独立危险因素(OR=3.852,95%CI 1.819-9.054,P=0.001)。
适用人群与场景
- 2018年3月至2020年1月在徐州医科大学附属常熟医院接受rt-PA静脉溶栓的急性缺血性卒中患者173例,按是否发生HT分为HT组46例和非HT组127例。
诊断标准与关键阈值
- 出血转化(HT)诊断标准原文未提及具体影像学或临床判定条件。
- 神经功能恢复(预后良好/不良)判定标准原文未提及具体量表界值。
- 多因素分析中HT的独立危险因素界值:年龄>69岁、溶栓前NIHSS>12分、发病至溶栓3.0-4.5小时。
- SUA>364.5 μmol/L为HT保护因素的界值;SUA>352.7 μmol/L和eGFR>102.5 mL×min-1×1.73 m-2为预后良好保护因素的界值。
处置流程与药物剂量
- 原文未提及具体溶栓药物剂量、给药途径、频次或疗程方案,仅说明患者接受rt-PA静脉溶栓。
- 原文未提及针对HT或预后不良因素的具体干预措施或目标值。
红旗征与不能漏的情况
- 溶栓前NIHSS>12分、年龄>69岁、发病至溶栓3.0-4.5小时的患者HT风险升高,需警惕并加强监测。
- 发生HT者预后不良风险升高(OR=3.852,95%CI 1.819-9.054,P=0.001),原文未提及具体处理措施。
研究设计与关键结果
- 研究类型:回顾性单中心研究;样本量173例(HT组46例,非HT组127例);单中心(徐州医科大学附属常熟医院)。
- 单因素分析:HT组eGFR(87.53±14.32 vs. 121.47±32.49 mL×min-1×1.73 m-2)和SUA(324.89±70.43 vs. 383.08±89.21 μmol/L)显著低于非HT组(均P<0.05);Fib(2.99±0.57 vs. 2.58±0.49 g/L)、年龄(70.32±5.87 vs. 65.28±7.09岁)、高血压比例(76.1% vs. 51.2%)、糖尿病比例(71.7%
- 多因素Logistic回归:SUA>364.5 μmol/L为HT保护因素(OR=0.607,95%CI 0.493-0.732,P=0.012);年龄>69岁(OR=2.470,95%CI 1.438-5.291,P=0.020)、溶栓前NIHSS>12分(OR=5.072,95%CI 1.793-12.468,P=0.001)、发病至溶栓3.0-4.5小时(OR=3.854,95%CI 1.600-5.816,P=0.005)为HT
- 预后分析:eGFR>102.5 mL×min-1×1.73 m-2(OR=0.663,95%CI 0.544-0.782,P=0.005)和SUA>352.7 μmol/L(OR=0.714,95%CI 0.603-0.825,P=0.014)为预后良好保护因素;年龄>70岁(OR=1.642,95%CI 1.173-3.512,P=0.038)、溶栓前NIHSS(OR=2.108,95%CI 1.356-4.438,P=0.022)、
证据类型、等级与局限
- 证据类型:回顾性单中心研究(论文)。
- 局限:单中心、回顾性设计、样本量173例;原文未提及盲法或前瞻性验证。
对床旁实践的改变
- 对拟行rt-PA静脉溶栓的AIS患者,溶栓前NIHSS>12分、年龄>69岁、发病至溶栓3.0-4.5小时提示HT风险升高,可据此加强溶栓后神经功能与影像监测。
- SUA>364.5 μmol/L与HT风险降低相关,但原文为回顾性相关性分析,不能据此在床旁补尿酸或改变溶栓决策。
- eGFR和Fib对HT无独立影响,不应单独作为HT风险分层依据。
- 适用人群为接受rt-PA静脉溶栓的AIS患者;原文未提及不适用人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the risk factors of neurological function recovery and occurrence of cerebral hemorrhage transformation (HT) after recombinant tissue-type plasiminogen activator (re-PA) in patients with acute ischemic stroke (AIS).
METHODS: The 173 patients with AIS who received rt-PA thrombolysis in Changshu Hospital of Xuzhou Medical University from March, 2018 to January, 2020 were selected as research objects, and they were divided into HT group (46 cases) and non HT group (127 cases) according to whether HT occurred. The data such as gender, age, body mass index (BMI), past histories including smoking, drinking, hypertension, diabetes mellitus, stroke, atrial fibrillation, coronary heart disease, National Institutes of Health Stroke Scale (NIHSS) score before thrombolysis, systolic blood pressure before thrombolysis, diastolic blood pressure before thrombolysis, hemoglobin, blood glucose, triglyceride, total cholesterol, thrombolytic time, responsible infarction, CT low density foci, estimated glomerular filtration rate (eGFR), serum uric acid (SUA) and fibrinogen (Fib) were collected. The differences of the above indexes were compared between the HT and non HT groups and the patients with different prognosis. The factors influencing the occurrence and neurological function recovery of HT were analyzed by multivariate Logistic regression.
RESULTS: (1) Univariate analysis showed that eGFR (mL×min-1×1.73 m-2): 87.53±14.32 vs. 121.47±32.49) and SUA (μmol/L: 324.89±70.43 vs. 383.08±89.21) in HT group were significantly lower than those in non HT group (both P < 0.05), Fib (g/L: 2.99±0.57 vs. 2.58±0.49), age (years old: 70.32±5.87 vs. 65.28±7.09), hypertension [76.1% (35/46) vs. 51.2% (65/127)], diabetes mellitus [71.7% (33/46) vs. 48.8% (62/127)], NIHSS before thrombolysis (13.42±2.97 vs. 10.18±1.85), proportion of thrombolytic time 3.0-4.5 hours [52.2% (24/46) vs. 38.6% (49/127)], and the proportion of CT low-density lesions [50.0% (23/46) vs. 22.0% (28/127)] in HT group were significantly higher than those in non HT group (all P < 0.05). In poor prognosis group, eGFR (mL×min-1×1.73 m-2: 92.08±22.37 vs. 116.59±24.57) and SUA (μmol/L: 332.58±59.03 vs. 370.34±63.46) were significantly lower than those in good prognosis group (both P < 0.05), Fib (g/L: 2.91±0.46 vs. 2.68±0.52), age (years old: 71.26±5.42 vs. 64.08±7.48), BMI (kg/m2: 24.32±3.68 vs. 23.18±3.16), the proportion of hypertension [69.7% (46/66) vs. 50.5% (54/107)], NIHSS before thrombolysis (12.98±3.02 vs. 10.32±2.14), proportion of thrombolytic time 3.0-4.5 hours [57.6% (38/66) vs. 32.7% (35/107)], proportion of CT low-density lesions [40.9% (27/46) vs. 22.4% (24/107)] were significantly higher than those in good prognosis group (all P < 0.05). (2) Multivariate Logistic regression analysis showed that SUA > 364.5 μmol/L was a protective factor for HT [odds ratio (OR) = 0.607, 95% confidence interval (95%CI) was 0.493-0.732, P = 0.012], age > 69 years old (OR = 2.470, 95%CI was 1.438-5.291, P = 0.020), NIHSS score before thrombolysis > 12 points (OR = 5.072, 95%CI was 1.793-12.468, P = 0.001), and time from onset to thrombolysis 3.0-4.5 hours (OR = 3.854, 95%CI was 1.600-5.816, P = 0.005) were independent risk factors for HT. No independent effects of eGFR and Fib on HT were observed (both P > 0.05); eGFR > 102.5 mL×min-1×1.73 m-2 (OR = 0.663, 95%CI was 0.544-0.782, P = 0.005) and SUA > 352.7 μmol/L (OR = 0.714, 95%CI was 0.603-0.825, P = 0.014) were protective factors for prognosis, and age > 70 years old (OR = 1.642, 95%CI was 1.173-3.512, P = 0.038), NIHSS score before thrombolysis (OR = 2.108, 95%CI was 1.356-4.438, P = 0.022) and HT (OR = 3.852, 95%CI was 1.819-9.054, P = 0.001) were risk factors for poor prognosis.
CONCLUSIONS: SUA is protective factor of HT and poor prognosis in patients with AIS after intravenous thrombolysis with rt-PA, eGFR is protective factor of poor prognosis, but it has no correlation with HT, Fib before thrombolysis has no correlation with HT and poor prognosis.
参考来源
- Chen Y, Zhang Q, You N, et al. [Analysis of influencing factors of neurological function recovery and cerebral hemorrhage transformation after intravenous thrombolysis in patients with acute ischemic stroke]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33463494. doi:10.3760/cma.j.cn121430-20200713-00517
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。